ClinicalTrials.gg
TerminatedNCT01864538Updated May 11, 2025Results posted

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

A Phase 2 interventional study of TH-302 in Metastatic Melanoma, sponsored by ImmunoGenesis. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by ImmunoGenesis · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 235 studies in Melanoma with a site in Canada — 28 open to participants now, 70 under way, 21 of them phase 3. Melanoma · Canada.

Enrollment
206th of 216
11 · median 160
Started
2013
with 14 others
Phase 2
60 of 235
6 open now
Registered
73rd of 235
by date

Among the 235 studies in Melanoma with a site in Canada, this one is the 206th largest by enrollment of the 216 interventional ones that give a count, is one of 15 that started in 2013, is one of 60 in phase 2, and was the 73rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

28 of the 235 studies in Melanoma with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Melanoma with a site in Canada, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.

Read the detailed description

Hypoxia is an independent marker of a poor prognosis for subjects with metastatic melanoma (Simonetti 2012, Lartigau 1997). Hypoxic melanoma cells are more likely to exhibit a stem-cell like phenotype with an associated increased propensity for invasion, angiogenesis, and metastasis formation compared to normoxic cells. Moreover, this phenotype is also associated with treatment resistance. TH-302, a hypoxia activated prodrug (HAP), was designed to target the hypoxic nature of tumours while having a minimal effect on normoxic tissue. TH-302 belongs to a class of alkylating agents that have significant experimental and clinical activity (Brock 1989). Preclinical data support the hypothesis that TH-302 targets hypoxic regions of tumours and is also able to kill tumour cells in normoxic regions as a result of cytotoxin diffusion, leading to significant effects on tumour growth (Meng 2011). TH-302 has been investigated in over 700 subjects with solid tumours or hematologic malignancies, including subjects with metastatic melanoma. In this subset a disease control rate of 63% (3 subjects with partial responses and 9 subjects with stable disease out of a total of 19) was observed in an early phase clinical trial of TH-302 (Weber 2010). Predictive biomarkers for response and toxicity have yet to be identified for subjects with advanced melanoma treated with TH-302. Optimal patient selection may be critical to maximize the clinical benefit. A predictive biomarker approach will be investigated to try to identify subjects most likely to benefit from TH-302. Given the hypoxia-targeting mechanism of TH- 302, it is believed that hypoxia biomarkers will be the most informative for identifying subjects likely to benefit from TH- 302; however, additional biomarkers including DNA repair biomarkers will also be investigated. In addition, this approach will also have potential to synergise with future immunotherapeutic approaches as suppressive T regulatory cells are thought to reside within hypoxic niches within the tumour microenvironment that would be amenable to targeting by TH-302.

03

Conditions studied

  • Metastatic Melanoma

Keywords

  • TH-302
  • Advanced Melanoma
  • Metastatic
  • Biomarker
  • Mucosal Melanoma
  • Evofosfamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age
  2. Ability to understand the purposes and risks of the study and has signed a written form approved by the investigator's Regional Ethics Board/Independent Ethics Committee (REB/IEC)
  3. documented cutaneous or mucosal malignant melanoma, which is recurrent or and is not curable by surgical or other means.
  4. Adequate tumour tissue (greater than 0.5cm3 preferred, 3 X core acceptable) available and agreement from subjects that this tissue from their primary and/or metastatic tumour be made available for assessment of potential biomarkers.
  5. Ability and availability to complete all prescribed biomarker studies (Screening and after Cycle 2).
  6. Recovered to Grade 1 from reversible toxicities of prior therapy
  7. Presence of clinically and/or radiologically documented disease. At least one site of disease (which will not be removed during the course of the study) must be uni-dimensionally measurable as per 1.1 or clinically quantifiable (such as in the case of skin disease)
  8. performance status of 0 - 1.
  9. Prior treatment with any number of immunotherapies (e.g., IL2, ipilimumab), targeted therapies (e.g., vemurafenib) are permitted but no more than one 1 prior chemotherapy
  10. Acceptable liver function
  11. Acceptable renal function
  12. Acceptable hematologic status (without growth factor support for neutropenia or transfusion dependency):
  13. Normal 12-lead (clinically insignificant abnormalities permitted)
  14. Female subjects of childbearing age must have a negative urine HCG test unless prior hysterectomy or menopause (defined as age above 55 and twelve months without menstrual activity). Female subjects should not become pregnant or breast-feed while on this study. Sexually active male and female subjects should use effective .

Exclusion criteria

Exclusion Criteria:

  1. Anticancer treatment with radiation therapy, targeted therapies, chemotherapy, immunotherapy, hormones or other antitumour therapies within 28 days prior to first dose of TH-302.
  2. Subjects who have received any other drug or agent within 28 days of first dose of TH-302
  3. Current use of drugs with known cardiotoxicity
  4. Significant cardiac dysfunction:
  5. Seizure disorders requiring anticonvulsant therapy
  6. Progressing (unless previously treated and stable disease for a period of greater than or equal to 3 months on repeat MRI following definitive treatment).
  7. History of other , except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for greater than 2 years
  8. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation less than 90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause hypoxia of normal tissue.
  9. Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery
  10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  11. Prior therapy with an hypoxic cytotoxin
  12. Known infection with or active infection with or
  13. History of allergic reaction to a structural compound or biological agent similar to TH-302
  14. Pregnancy or breast-feeding
  15. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  16. Unwillingness or inability to comply with the study protocol for any reason.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    TH-302

    480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.

    Drug: TH-302

Interventions

  • DrugTH-302

    480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: 1 year

07

Results

Posted Aug 16, 2017

Participant flow

Participant flow — Overall Study
MilestoneTH-302
Started11
Completed0
Not completed11

Outcome measures

PrimaryOverall Survival
Time frame:
1 year
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsTH-302
Overall Survival11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TH-302—8/11 (72.7%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventTH-302
CellulitisInfections and infestations1/11
Urinary tract infectionInfections and infestations1/11
AnaemiaBlood and lymphatic system disorders1/11
Splenic thrombosisBlood and lymphatic system disorders1/11
Abdominal distensionGastrointestinal disorders1/11
ConstipationGastrointestinal disorders1/11
Back painMusculoskeletal and connective tissue disorders1/11
FatigueGeneral disorders1/11
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTH-302
Decreased appetiteMetabolism and nutrition disorders6/11
FatigueGeneral disorders6/11
ConstipationGastrointestinal disorders4/11
Oedema peripheralGeneral disorders4/11
Upper respiratory tract infectionInfections and infestations3/11
HeadacheNervous system disorders3/11
DyspnoeaRespiratory, thoracic and mediastinal disorders3/11
DiarrhoeaGastrointestinal disorders3/11
NauseaGastrointestinal disorders3/11
RashSkin and subcutaneous tissue disorders3/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TH-302
<=18 years0
Between 18 and 65 years11
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)TH-302
Female8
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TH-302
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)TH-302
Canada3
United States8
08

Study locations

7 sites
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • UCLA
    Los Angeles, California 90404, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G1Z2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V5C2, Canada
  • London Health Sciences Centre
    London, Ontario N6A4L6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G2M9, Canada
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Sep 2015, 28 months.

Results were first posted in Aug 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2013
First posted
May 29, 2013
StartActual
May 2013
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Aug 16, 2017
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01864538
Lead sponsor
ImmunoGenesis
Responsible party
Sponsor
First posted
May 29, 2013
Start date
May 2013
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Aug 16, 2017
Last update
May 11, 2025

Study contacts

Tillman Pearce, MD
study director · Threshold Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion